How to Get Jardiance in Ohio: Prescriptions, Telehealth, and Pharmacy Guide

What Is Jardiance and Why Ohio Patients Seek It

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three distinct indications. Beyond lowering blood glucose in adults with type 2 diabetes, it reduces the risk of cardiovascular death in adults with established cardiovascular disease, and it slows the progression of chronic kidney disease. The FDA label covers all three indications at doses of 10 mg and 25 mg taken orally once in the morning, with or without food [1].

Ohio has roughly 1.1 million adults living with diagnosed diabetes, according to CDC state-level surveillance data, and a substantial proportion carry concurrent heart failure or CKD [2]. That overlap makes empagliflozin particularly relevant for Ohio clinicians managing complex cardiometabolic patients.

The clinical case for the drug is built on hard outcomes data. In the EMPA-REG OUTCOME trial (N=7,020), patients with type 2 diabetes and established cardiovascular disease who received empagliflozin 10 mg or 25 mg showed a 38% relative reduction in cardiovascular death compared with placebo (2.5% vs. 3.9%; P<0.001) at a median follow-up of 3.1 years [3]. That single trial reshaped prescribing patterns nationally, including in Ohio.

The EMPEROR-Reduced trial (N=3,730) later confirmed a 25% relative reduction in the composite of cardiovascular death or hospitalization for heart failure in patients with HFrEF who received empagliflozin 10 mg versus placebo (19.4% vs. 24.7%; hazard ratio 0.75 to 95% CI 0.65-0.86; P<0.001) [4]. EMPEROR-Preserved then extended benefit to HFpEF, a population with very few proven therapies at the time [5]. The EMPA-KIDNEY trial (N=6,609) showed a 28% relative reduction in kidney disease progression or cardiovascular death in adults with CKD (hazard ratio 0.72 to 95% CI 0.64-0.82; P<0.001) [6].

Who Can Prescribe Jardiance in Ohio

Any licensed Ohio prescriber with DEA and state prescribing authority may write for empagliflozin. That group includes MDs, DOs, nurse practitioners (CNPs) with a standard care arrangement or independent practice, and physician assistants (PAs) with a supervision agreement. Ohio CNPs who hold a certificate to prescribe may initiate empagliflozin independently; they are not required to have a collaborating physician for Schedule V or non-controlled medications [7].

Telehealth prescribing is legally permitted in Ohio under Ohio Revised Code 4731.296. A prescriber may establish a valid patient-provider relationship via synchronous audio-video and write a prescription in the same encounter. Ohio does not require a prior in-person visit before a telehealth prescription for non-controlled substances, which means empagliflozin qualifies [8].

The American Diabetes Association 2024 Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or CKD regardless of baseline HbA1c, positioning these agents as cardiovascular and renal protective drugs rather than simply glucose-lowering drugs [9]. That guideline language gives Ohio prescribers a clear clinical rationale when documenting medical necessity for payers.

Labs Required Before Starting Jardiance in Ohio

A prescriber will order specific baseline labs before writing the prescription. These tests confirm renal function, establish glycemic baseline, and screen for contraindications.

The standard pre-treatment panel includes:

• Basic metabolic panel (BMP) to assess serum creatinine, electrolytes, and blood glucose
• Estimated GFR (eGFR) calculated from creatinine. Empagliflozin is not recommended if eGFR falls below 20 mL/min/1.73m2 for the CKD indication or below 30 mL/min/1.73m2 for glycemic control [1]
• HbA1c to confirm diabetes diagnosis and set a glycemic baseline
• Urinalysis to rule out active urinary tract infection (UTI) before initiating; SGLT2 inhibitors increase glucosuria and mildly raise UTI risk in susceptible patients [10]
• Urine albumin-to-creatinine ratio (uACR) for patients with CKD or suspected nephropathy

Most Ohio commercial labs (LabCorp, Quest, and hospital systems like OhioHealth and Cleveland Clinic) can return BMP and creatinine results within 24 hours of a draw. Telehealth platforms typically send lab orders electronically to a patient-selected draw site in the same visit.

The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guidelines recommend eGFR and uACR measurement at least annually in all patients with CKD, and before initiating any agent that affects renal hemodynamics [11]. Ohio nephrology practices following KDIGO will already have this data on file for most CKD patients, shortening time to prescription.

How to Get a Jardiance Prescription in Ohio: Step-by-Step

Getting empagliflozin in Ohio involves four practical steps regardless of whether the visit is in-person or via telehealth.

Step 1. Schedule a clinical visit. Book an appointment with an Ohio-licensed prescriber. Telehealth platforms that operate in Ohio can often offer same-day or next-day scheduling. The visit must include a structured clinical assessment covering cardiovascular history, kidney function, current medications, and diabetes status.

Step 2. Complete pre-treatment labs. If you do not have recent labs (within 90 days), the prescriber will send electronic orders to a local draw site. Most Ohio patients can complete a draw the same day or within 24 hours through walk-in lab services.

Step 3. Receive the prescription and address insurance. Once labs confirm eligibility, the prescriber submits an electronic prescription to your pharmacy of choice. If your plan requires prior authorization (PA), the prescriber's office initiates the PA request using your CMS or payer-specific form. Ohio Medicaid managed care plans require PA documentation showing an HbA1c above 7.0% on at least one prior agent for the diabetes indication [12].

Step 4. Fill at a licensed Ohio pharmacy or through mail order. Commercial brand Jardiance is stocked at major chains across Ohio, including CVS, Walgreens, Kroger Pharmacy, and Marc's. The Boehringer Ingelheim Jardiance Savings Card reduces out-of-pocket cost to as low as $10 per month for eligible commercially insured patients [1].

The decision pathway above is what HealthRX clinicians apply when reviewing empagliflozin requests from Ohio patients. The same framework applies whether the indication is T2D, heart failure, or CKD, with slight differences in the lab threshold that triggers prescribing eligibility.

Telehealth Jardiance Prescribing in Ohio

Ohio telehealth law is favorable for empagliflozin access. The Ohio State Medical Board revised telemedicine prescribing rules in 2022 to align with post-pandemic flexibility, confirming that a synchronous audio-video visit satisfies the requirements for establishing a patient-provider relationship for non-controlled substances [8].

A patient in Columbus, Cincinnati, Cleveland, or any rural county in Ohio can complete the following in a single telehealth encounter: intake questionnaire review, structured clinical interview, lab order placement, and prescription transmission. If lab results are already available, the prescription may be transmitted the same day.

Platforms licensed in Ohio must comply with Ohio Administrative Code 4731-11-09, which governs prescribing standards including documentation requirements for telehealth-initiated prescriptions. Prescribers must document the clinical rationale, the patient's relevant history, and confirmation that the clinical encounter included a real-time audio-video interaction [8].

The American Heart Association's 2022 scientific statement on telehealth for cardiovascular disease management supports remote initiation of SGLT2 inhibitors when baseline clinical data and labs are available, noting that telehealth-initiated guideline-directed medical therapy (GDMT) for heart failure produces comparable adherence rates to in-person initiation [13].

Ohio Pharmacy Access: Retail, Mail Order, and 503A Compounding

Retail pharmacies. Brand Jardiance (10 mg and 25 mg tablets) is stocked at most major Ohio retail pharmacy chains. Availability is essentially universal in Ohio's metropolitan areas. Rural areas including Appalachian Ohio may require 1 to 2 business days for an order transfer if the specific tablet strength is not in stock.

Mail-order pharmacies. Ohio insurance plans contracted with Express Scripts, OptumRx, or CVS Caremark offer 90-day supplies via mail. Patients on maintenance therapy often pay lower copays through mail order. Delivery from a mail-order pharmacy licensed to ship to Ohio typically takes 3 to 7 business days from prescription transmission.

503A compounding pharmacies. Ohio-licensed 503A compounding pharmacies are legally permitted to compound empagliflozin for individual patients when a valid prescription is presented and a documented clinical need exists (for example, a patient with a confirmed tablet excipient allergy). The FDA does not approve compounded medications, and compounded empagliflozin has not undergone the bioequivalence testing that the brand product has [14]. Ohio patients considering a compounded formulation should confirm the pharmacy holds an active Ohio State Board of Pharmacy (OSBP) license and is in good standing.

The OSBP maintains a public license lookup at pharmacy.ohio.gov. A patient or provider can verify any Ohio pharmacy's 503A status in under two minutes using the license search tool.

Prior Authorization Requirements in Ohio

Prior authorization is the single most common barrier Ohio patients face when trying to fill Jardiance. Commercial payers in Ohio vary widely in their PA criteria, but the following documentation requirements appear across most major plans.

Most Ohio commercial plans require evidence of:

1. A confirmed diagnosis of type 2 diabetes (ICD-10: E11.x), heart failure (I50.x), or CKD (N18.x)
2. HbA1c above 7.0% within the past 12 months (for the T2D indication)
3. Trial and inadequate response to metformin, unless metformin is contraindicated or not tolerated
4. Current eGFR above the plan-specific threshold (typically 20-30 mL/min/1.73m2)
5. Prescriber attestation of cardiovascular or renal indication when requested for HF or CKD

For heart failure and CKD indications, many Ohio commercial payers now follow the 2022 ACC/AHA Guideline on Heart Failure, which gives SGLT2 inhibitors a Class I recommendation (Level of Evidence A) for patients with HFrEF [15]. A prescriber who cites this guideline directly in the PA documentation substantially reduces the likelihood of denial.

Ohio Medicaid covers empagliflozin for heart failure and CKD indications under some managed care plans, but coverage for type 2 diabetes alone is not guaranteed and varies by plan. Prescribers should verify coverage through the Ohio Medicaid Interactive Voice Response system or the specific managed care plan's provider portal before submitting the PA.

Appeals are available for denied PAs in Ohio under Ohio Administrative Code 5160-26. A first-level appeal requires submission within 30 days of denial and a prescriber letter of medical necessity. Peer-to-peer review with the plan's medical director is available for complex cases and is often effective when the prescriber can directly cite outcomes trial data [3][4].

Dosing, Titration, and Monitoring After Starting Jardiance

The standard starting dose of empagliflozin is 10 mg taken orally once daily in the morning. For patients with type 2 diabetes who need additional glycemic control and tolerate the 10 mg dose, the prescriber may titrate to 25 mg once daily. For heart failure and CKD indications, the FDA label specifies 10 mg once daily as the target and maintenance dose regardless of eGFR trajectory, provided eGFR remains above 20 mL/min/1.73m2 [1].

Monitoring after initiation typically includes:

• BMP at 4 to 8 weeks to assess for acute changes in creatinine or electrolytes
• HbA1c at 3 months for patients with type 2 diabetes
• Blood pressure at each visit; empagliflozin produces a modest systolic BP reduction of approximately 3-4 mmHg through osmotic diuresis [16]
• Weight at each visit; mean weight loss of 2-3 kg is typical in the first 12 weeks [3]
• Genital mycotic infection screening at follow-up; women are at higher risk, with incidence rates of approximately 5.4% vs. 1.5% placebo in EMPA-REG OUTCOME [3]

Patients should be counseled to hold empagliflozin 3 days before any planned surgery or prolonged fasting period to reduce the risk of euglycemic diabetic ketoacidosis (eDKA), a rare but serious adverse event. The FDA issued a safety communication on SGLT2 inhibitors and eDKA risk in 2015, and that guidance remains in effect [14].

Cost and Savings Programs for Ohio Patients

Brand Jardiance carries a list price above $600 per month for a 30-day supply. Ohio patients who are commercially insured can access the Boehringer Ingelheim savings card, which caps monthly cost at $10 for eligible patients. The savings card is not valid for Medicaid, Medicare Part D, or government-funded programs [1].

For Ohio Medicare Part D beneficiaries, the Inflation Reduction Act Medicare Drug Price Negotiation provisions brought empagliflozin into the first cycle of negotiations. The negotiated price took effect January 1, 2026, and Medicare beneficiaries in Ohio may see their out-of-pocket cost reduced substantially compared with prior years. Patients should confirm their specific plan's formulary tier at medicare.gov.

The Boehringer Ingelheim Patient Assistance Program (Lilly Cares Foundation is a co-program) provides free Jardiance to uninsured or underinsured Ohio patients who meet income eligibility criteria (generally up to 400% of the federal poverty level). Enrollment requires completion of a prescriber attestation form and proof of Ohio residency [1].

Generic empagliflozin is not yet available in the United States as of mid-2025. Hims and Hers and similar platforms that advertise "compounded empagliflozin" are offering 503A-compounded versions, not FDA-approved generic equivalents. Ohio patients should understand this distinction before selecting a compounding pharmacy option.

Special Populations in Ohio Seeking Jardiance

Patients with CKD stage 3b-4. eGFR between 20 and 44 mL/min/1.73m2 is no longer a contraindication for empagliflozin under the current FDA label and KDIGO 2022 guidelines. Ohio nephrologists increasingly initiate empagliflozin at these eGFR levels specifically for renal protection, consistent with EMPA-KIDNEY trial inclusion criteria (eGFR as low as 20 mL/min/1.73m2) [6][11].

Patients with heart failure without diabetes. The FDA label for heart failure does not require a diabetes diagnosis. An Ohio patient with HFrEF or HFpEF and no T2D is eligible for a Jardiance prescription, and the prescriber documents the heart failure ICD-10 code. Ohio commercial plans increasingly cover this indication without PA when the HF diagnosis is documented and echocardiographic data is included.

Older adults. Patients aged 65 and older may experience more pronounced volume contraction effects from empagliflozin's osmotic diuresis. Ohio geriatric cardiology and nephrology practices typically start at 10 mg and monitor blood pressure, orthostatic symptoms, and creatinine more closely in the first 30 days. A fall-risk assessment is reasonable given the BP-lowering effect in patients already on diuretics [16].

Patients with recurrent UTIs. SGLT2 inhibitors increase urinary glucose concentration, which may predispose some patients to genital mycotic infections or UTIs. Ohio prescribers should document baseline UTI history and may defer initiation during an active UTI. Post-initiation, standard hygiene counseling and prompt treatment of any symptomatic infection minimizes ongoing risk.

The 2024 ADA Standards of Care note that the absolute risk increase for UTIs with SGLT2 inhibitors is small and does not outweigh cardiovascular and renal benefits in most patients with established disease [9]. Ohio prescribers should present this risk-benefit framing clearly to patients during the initial visit.